Genovis signs license agreement with Life Technologies Corporation

Genovis has entered into a license agreement with Life Technologies a wholly
owned subsidiary of Thermo Fisher Scientific and is launching a unique new
technology for labeling antibodies. The first product, GlyCLICK™, will be
launched in the autumn.
Labeling of antibodies includes several elements in the chain from development,
preclinical, diagnostic and therapeutic applications in the pharmaceutical
industry. By combining Genovis’ unique enzymes with SiteClick™ technology from
Life Technologies antibodies will be labeled precisely and completely at the
same site each time, regardless of the type of antibody or its origin. Genovis
will focus sales and marketing resources for GlyCLICK on the preclinical market
in the biopharma industry where the company already has the majority of its
customer base. Initially, the technology will be marketed in the market for
preclinical imaging. The reagent market for this segment is estimated to be
approximately USD 500 million for 2017 (Markets and Markets).

“I am very pleased about the collaboration with Life Technologies, which now
gives us a unique and extremely interesting product. We will establish the
product within preclinical research, though we see several potential clinical
applications moving forward. The field of diagnostic applications is
interesting, but the next generation of antibody drugs, known as Antibody Drug
Conjugates (ADC), could also benefit from the new technology platform, which
offers a precise and exact end product that the industry has been requesting,”
says Fredrik Olsson, CEO of Genovis.

MORE ABOUT LABELING ANTIBODIES

Labeling antibodies with various markers is a technique used in several areas of
pharmaceutical research and development. With the technology currently available
in the market, the marker can attach randomly in different places on the
antibody, and in many cases it could have a negative effect on the function of
the antibody. In addition, the position of the marker may vary depending on the
antibody that is labeled. Using the new GlyCLICK™ technology platform, the label
always attaches at precisely the same site and it is possible to label with many
different markers, which makes the technology both versatile and scalable.

For more information about GlyCLICK™: http://www.genovis.com/products/glyclick/

SiteClick™

SiteClick™ is provided under an intellectual property license from Life
Technologies Corporation. The trademark SiteClick™ is the property of Life
Technologies Corporation.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)

This information is information that Genovis AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, by the contact person set out above, on October 11, 2016.
ABOUT GENOVIS

Genovis is a global company that offers enzyme products that facilitate
development and quality control of biologics to customers in the pharmaceutical
and medical technology industries. The Company markets several enzyme products
(“SmartEnzymes”) in innovative product formats all over the world.

The organization consists of Genovis AB and the wholly owned subsidiary Genovis
Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North
American market and Genovis AB handles sales in the rest of the world. Genovis
shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s
Certified Adviser, t: +46(0) 31 745 50 00.

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.